This past Tuesday, the U.S. Food and Drug Administration (FDA) updated the emergency use authorizations (EUAs) of Moderna’s and Pfizer-BioNTech’s COVID-19 bivalent vaccines. The predominate changes made by the FDA is the authorization of the current bivalent vaccines for all doses administered to individuals 6 months and older and the authorization of a second bivalent booster dose for adults aged 65 and older and those with certain kinds of immunocompromise. In turn, the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) met to discuss the implementation of the FDA’s new authorization and provided updated recommendations.
FDA’s News Release: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines
CDC’s Updated Recommendations: https://www.cdc.gov/media/releases/2023/s0419-covid-vaccines.html
